The Current Treatment Landscape in CLL With the Advent of Novel Therapy Agents
Dr Mazyar Shadman reviews emerging targeted therapies shaping the treatment landscape and optimal sequencing in CLL.
EP: 1.Factors for Consideration When Choosing a Treatment for Patients With CLL
Now Viewing
EP: 2.The Current Treatment Landscape in CLL With the Advent of Novel Therapy Agents
EP: 3.BTK Inhibitor Investigations in the Frontline Treatment of CLL: Updates from ASH 2023
EP: 4.Emergent Data from the ALPINE Trial Investigating Zanubrutinib in the Treatment of Relapsed/Refractory CLL
EP: 5.The Evolving Treatment Landscape in Relapsed/Refractory CLL
EP: 6.Improving Outcomes in CLL with BTK Inhibitors: Navigating Adverse Events, Sustaining Treatment, and Future Outlook in Relapsed/Refractory Disease
Related Videos
Related Content
Marks Explores Cardiac Toxicities and Dosing Concerns of BTK Inhibitors in CLL
April 26th 2024Article
During a Case-Based Roundtable® event, Stanley M. Marks, MD, moderated a discussion on the impact of cardiac adverse events on patients who receive a Bruton tyrosine kinase inhibitor for chronic lymphocytic leukemia.
Read More
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024Article
In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
